Newsroom

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”), a mid-cap growth and value biotech company, today announced the commencement of an underwritten public offering of $250.0 million of shares of its common stock. In addition, Twist intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock. All of the shares of common stock to be sold in the proposed offering are being offered by...

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today reported its second quarter 2026 financial results and provided a corporate update. “With an exceptional second quarter, Travere has entered a new chapter of near- and long-term growth,” said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics. “Our performance reflects the strength of the company we are building and the disciplined execution of our teams as we continue to deliver on our stra...

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the second quarter ended June 30, 2026, and highlighted recent business accomplishments. Second Quarter and Recent Strategic and Operational Highlights Secured Medicare Coverage for IO Monitoring: Received Medicare coverage approval for NeXT Personal for immunotherapy monitoring for patients with late-stage solid tumors. Se...

BOSTON--(BUSINESS WIRE)--OneSpan Inc. (NASDAQ: OSPN) today reported financial results for the second quarter ended June 30, 2026. “We delivered a strong second quarter highlighted by double-digit subscription revenue growth and strong profitability,” stated OneSpan CEO Victor Limongelli. “Importantly, two weeks ago we introduced DigipassONE, a unified authentication platform that builds on the broadest suite of authentication functionality in the market with our new offering for verifiable cred...

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 12,555 shares of the Company’s common stock to four new employees (the “Inducement Grants”) on August 3, 2026 (the “Grant Date”). The Induce...

NASHVILLE, Tenn.--(BUSINESS WIRE)--Bed Bath & Beyond, Inc. (NYSE: BBBY) (“Bed Bath & Beyond” or “BBBY”) has issued the following letter from Marcus Lemonis, Executive Chairman and Chief Executive Officer of Bed Bath & Beyond: To Our Shareholders, Somewhere tonight, there will be a family at a kitchen table with a laptop open and a stack of statements between them. They will call it the family plan, and what it really is, is a monthly profit and loss statement for a household: the ca...

ORLANDO, Fla.--(BUSINESS WIRE)--Marriott Vacations Worldwide Corporation (“MVW”) (NYSE: VAC) today announced the appointment of Vladimir “Vlad” Anokhin as Chief Strategy & Transformation Officer. Anokhin reports to Chief Executive Officer Matt Avril and serves as a member of the company's Executive Leadership Team. In this role, Anokhin leads transformation initiatives, data analytics, enhanced adoption of artificial intelligence capabilities, and product development. “Vlad offers a unique...

ROCHESTER, N.Y.--(BUSINESS WIRE)--Transcat Reports Strong Fiscal First Quarter 2027 Results with Double-Digit Service Organic Revenue Growth and Service Gross Margin Expansion...

NASHVILLE, Tenn.--(BUSINESS WIRE)--Bed Bath & Beyond, Inc. (NYSE:BBBY), owner of Bed Bath & Beyond, Overstock, buybuy BABY, the Kirkland’s and Kirkland's Home brands, and more recently The Container Store, Elfa, Closet Works, and SFV Services, as well as a blockchain asset portfolio, today reported financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Highlights Net revenue was $361 million, an increase of 28.0% year-over-year, marking the Company’s second co...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter 2026. “Gilead delivered a very strong second quarter, with 10% year-over-year revenue growth in our base business driven by our HIV portfolio, Trodelvy and Livdelzi. HIV sales grew 12%, reflecting continued strength in treatment and the rapid expansion of our PrEP business, supporting an increase in our base business revenue expectations for 2026,” said Dan...